{
}
Alnylam Pharmaceuticals reported mixed Q3 earnings for the quarter ending September 30, 2024, with net product revenues rising to $420.1 million, up from $313.2 million the previous year. However, the company faced a net loss of $111.6 million, a decline from a net income of $147.8 million, primarily due to increased research and development expenses. Strategic collaborations with companies like Roche and Regeneron are expected to bolster future growth as Alnylam focuses on expanding its RNAi therapeutics pipeline.
Alnylam Pharmaceuticals reported a Q3 loss of $0.50 per share, matching estimates, and a significant drop in revenues to $500.92 million, missing expectations by 5.37%. Despite outperforming the market with a 47.1% gain this year, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Current consensus estimates for the next quarter are -$0.44 EPS on $548.32 million in revenues.
David Baker, Demis Hassabis, and John Jumper have won the Nobel Prize in Chemistry for their groundbreaking work in computational protein design and structure prediction, significantly advancing drug design capabilities. Alnylam Pharmaceuticals seeks FDA approval for vutrisiran to treat a severe form of transthyretin amyloidosis, while Johnson & Johnson halts a bladder cancer trial for TAR-200. AstraZeneca invests in a preclinical cholesterol-lowering drug, and Astellas acquires rights to an experimental gene therapy for frontotemporal dementia.
Alnylam Pharmaceuticals, Inc.
Companies
| Symbol | ALNY |
| Name | Alnylam Pharmaceuticals, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | MA |
| City | Cambridge |
| Zipcode | 2142 |
| Website | http://www.alnylam.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Alnylam Pharmaceuticals reports mixed Q3 earnings amid rising product revenues
United States Dollar
Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
USA
Roche
Regeneron Pharmaceuticals
Show more
05:23 01.11.2024
Alnylam Pharmaceuticals reports Q3 loss and misses revenue expectations
14:10 31.10.2024
nobel prize awarded for protein design and drug developments advance
United States Dollar
Eli Lilly and Company
AviadoBio
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Amgen Inc.
Astellas Pharma Inc.
Pfizer Inc.
BridgeBio Pharma, Inc.
Novartis AG
AstraZeneca PLC
Johnson & Johnson
USA
SWE
JPN
BRA
HKG
John Jumper
David Baker
Jonathan Gardner
Demis Hassabis
Jim Wilson
Show more
13:00 09.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
Stock Market Updates
Government Economic Policies
Industry Mergers & Acquisitions
Energy Sector Developments
Workplace Trends
Funding Rounds & Investments
CEO Changes
AI Applications
Private Equity Deals
Emerging Startups
Fintech Startups
AI Innovations
Global Financial Events
Central Bank Actions
Countries:
Companies:
Apple Inc.
Google Inc.
Tesla, Inc.
Amazon.com, Inc.
Microsoft Corporation
Tesmec S.p.A.
Alphabet Inc.
OpenAI ERC USD
Walmart Inc.
SWIGGY LIMITED
TENCENT
NVIDIA Corporation
Foxconn Technology Co., Ltd.
Hollywood Bowl Group PLC
NASDAQ Composite
Wise plc
Mastercard Inc
Bose Corporation
Mistral 1
Fast Retailing Co., Ltd.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
British Pound Sterling
United Arab Emirates Dirham
Vietnamese Đồng
South Korean Won
New Zealand Dollar
Saudi Riyal
Thai Baht
Australian Dollar
Indonesian Rupiah
Singapore Dollar
Omani Rial
Bahraini Dinar
Qatari Riyal
Algerian Dinar
Egyptian Pound
People: